INVESTORS CREATING VALUE FOR STAKEHOLDERS We are an established, commercial-stage diagnostics company. We are an established, commercial-stage diagnostics company with over 30 years’ experience of manufacturing and supplying the conventional reagent products used for blood grouping within the $3.4 billion global transfusion diagnostics market. Our proprietary technology platform, MosaiQ, is continually been developed and enhanced to better address the comprehensive needs of this large and established market. We believe MosaiQ has the potential to be a transformative technology that significantly reduces the cost of blood grouping in both donor and patient-testing environments. Investors 1:00 PM EDT • NOV 26, 2021 QTNT 2.12USD -6.61% Contact Ali Kiboro, Chief Financial Officer IR@quotientbd.com 3 MONTHS 6 MONTHS 12 MONTHS Quotient Ltd $ Events & presentations 8:00 AM EST • NOVEMBER 24, 2021 24 NOV SFTS Congress 2021 3:30 AM EST • NOVEMBER 16, 2021 16 NOV Quotient Limited to Participate in the Jefferies London Healthcare Conference READ ALL EVENTS & PRESENTATIONS Press releases NOV 19, 2021 Quotient Limited Announces Equity Awards Read More NOV 15, 2021 Quotient Limited Provides Second Quarter Fiscal 2022 Results Read More NOV 12, 2021 Quotient Limited to Participate in the Jefferies London Healthcare Conference Read More READ ALL PRESS RELEASES Financials & filings Get up-to-date information about our Company’s financials. Learn More Corporate governance Retrieve corporate policy documents, committee charters, and more. Learn More Stock information Follow our latest stock quote and historical information. Learn More OUR REAGENTS BY QUOTIENT Alba by Quotient. Experience. Expertise. Value. LEARN MORE MENU QUICK ACTIONS Linkedin Twitter Vimeo THE FUTURE, MADE POSSIBLE. © Copyright 2021, All Rights Reserved. PRIVACY POLICY LEGAL NOTICE We use cookies on this site to enhance your user experience By clicking the Accept and Proceed button, you agree to our privacy policy. ACCEPT AND PROCEED